Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Solid State Boost at Onyx

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Company unveils huge increase in demand for solid-state chemistry services.

Onyx Scientific has unveiled a huge increase in demand for its solid-state chemistry services versus last year.

The contract research and manufacturing organization has reported a 45% uplift in solid formulation related revenues, which is being driven by early stage drug development projects.

The company’s close alliance with Molecular Profiles, announced last year, has also led to more work as a result of increasing activity in the biotechnology and early stage clinical sector.

Denise Bowser, commercial director at Onyx Scientific, said: “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable.

“As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form, is vital. This is why we feel we have seen such an increased demand.”

In 2013, the company has worked with pharmaceutical and biotech clients across the globe assisting with integrated chemistry, process development and custom synthesis projects.

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Its UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CRO to Expand GMP Capability
Company will install a new Class 100,000 suite at its facility in North East England.
Thursday, April 02, 2015
Onyx to Expand Capabilities
Reach alliance broadens specialist purification, separation services.
Tuesday, August 07, 2012
Onyx Strengthens Commercial Team
Appointment of Brian Jolly as director of European business development.
Monday, May 28, 2012
API Firm Posts Impressive Growth
UK-based Onyx Scientific has grown 27% as the business continues to build its pharmaceutical and biotech client-based in Europe, Japan and the US.
Thursday, June 02, 2011
Onyx Scientific Clinches Cancer Research UK Contract
Cancer Research UK has selected Onyx Scientific to develop the chemistry and perform the GMP synthesis of the API for use in a Phase 1 clinical trial.
Thursday, May 12, 2011
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!